Related Experiment Video
Updated: Apr 27, 2026

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy
Anna Elisabetta Brunetti1, Sabina Delcuratolo2, Vito Lorusso3
1Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", Bari, Italy brunetti.ae@gmail.com.
Background:
Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option.
Case Report:
Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery.
Results:
The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery.
Conclusion:
Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease.
Insights
Trabectedin, a marine-derived drug, showed prolonged partial response in a heavily pre-treated patient with desmoplastic small round cell tumour (DSRCT). This suggests trabectedin as a potential option for managing this rare cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Desmoplastic small round cell tumour (DSRCT) is an aggressive cancer primarily affecting young males, with limited treatment options and poor prognosis.
- Current DSRCT management involves intensive multi-agent chemotherapy, surgery, radiation, and potentially autologous stem cell transplantation or HIPEC.
Observation:
- A single patient with heavily pre-treated DSRCT, refractory to conventional therapies, received third-line treatment with trabectedin.
- Trabectedin is a marine-derived antineoplastic agent with multi-target activity.
Findings:
- The patient experienced a prolonged partial response and an extended period of stable disease after trabectedin administration.
- This response was observed following disease progression despite prior multi-agent chemotherapy, HIPEC, and surgery.
Implications:
- Trabectedin demonstrates potential as a valuable component in the multimodal treatment strategy for DSRCT.
- Further research is warranted to investigate the efficacy and impact of trabectedin in DSRCT management.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:43Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules